---
title: "Ivonescimab: EGFR-mutated non-small-cell lung cancer"
description: "Formulary evidence on Ivonescimab in EGFR-mutated non-small-cell lung cancer. Clinical evidence covers HARMONi, HARMONi-A, AK112-201, MARIPOSA-2, KEYNOTE-789, CheckMate 722, and 7 further headings. 226 evidence topics quoted from 73 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:23-05:00"
---

# Ivonescimab: EGFR-mutated non-small-cell lung cancer

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Ivonescimab

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of EGFR-mutated non-small-cell lung cancer

<a id="topic-1.1.1-1"></a>

##### Summary

An estimated 10–15% of NSCLC cases have an EGFR mutation. This proportion is not a population incidence rate. NSCLC symptoms include persistent cough, dyspnea, chest pain, fatigue, appetite loss, and weight loss. In a U.S. claims study including 409 participants with EGFR-mutated advanced NSCLC, mean all-cause healthcare costs per patient per month were $27,751 during first-line treatment, $28,971 during second-line treatment, and $31,251 during third-line treatment. These are disease-management costs, not estimates of the cost of ivonescimab.

Source: [Vanderpoel et al. (2023)](https://link.springer.com/article/10.1007/s41669-023-00407-0); [MedlinePlus non-small cell lung cancer](https://www.medlineplus.gov/ency/article/007194.htm); [Waterhouse et al. (2025)](https://jheor.org/article/142771-healthcare-resource-use-healthcare-costs-and-unmet-needs-among-patients-treated-for-egfr-mutated-advanced-or-metastatic-non-small-cell-lung-cancer)

<a id="heading-1.1.2"></a>

#### 1.1.2 Ivonescimab Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

HARMONi randomized 438 participants. In the 345-participant primary PFS analysis, median PFS was 6.8 months with ivonescimab plus chemotherapy and 4.4 months with placebo plus chemotherapy, with an HR of 0.52. The primary OS comparison was not statistically significant: median OS was 16.8 versus 14.0 months, with an HR of 0.79 and p=0.057. Grade 3 or higher TRAEs occurred in 50.0% versus 42.2%.

In HARMONi-A, 322 participants were randomized. Final median OS was 16.8 versus 14.1 months, with an HR of 0.74 and P=.02. Grade 3 or higher TEAEs occurred in 67.1% versus 54.7%. TEAEs and TRAEs are different safety measures and should not be treated as interchangeable.

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/); [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx); [HARMONi-A Study Investigators (2026)](https://pubmed.ncbi.nlm.nih.gov/42307937/)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Ivonescimab

No evidence found.

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

The phase 3 evidence supports a PFS benefit over chemotherapy alone in the studied post-EGFR-TKI population. HARMONi-A reported a statistically significant final OS result, whereas HARMONi did not meet its primary OS comparison. The later HARMONi HR of 0.76 is an updated follow-up result and should be distinguished from the primary test. Grade 3 or higher adverse events were more frequent in the ivonescimab groups, using each trial’s reported safety definition.

Ivonescimab has marketing authorization in China. On November 15, 2026, one day after the November 14, 2026 FDA goal date, Summit announced that the FDA had issued a complete response letter for the U.S. application, citing the absence of a statistically significant OS improvement in HARMONi. The economic evidence in this report includes a cost-effectiveness model.

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/); [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx); [HARMONi-A Study Investigators (2026)](https://pubmed.ncbi.nlm.nih.gov/42307937/); [Summit Therapeutics HARMONi updated overall survival announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study/default.aspx); [Summit Therapeutics China NMPA approval announcement (2024)](https://www.prnewswire.com/news-releases/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy-302161109.html); [Summit Therapeutics BLA acceptance announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx); [Long et al. (2025)](https://tlcr.amegroups.org/article/view/100492/html); [Summit Therapeutics complete response letter announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx)

## Related pages
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Terms and abbreviations](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations.md)
- [Ivonescimab: EGFR-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/executive-summary.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Product information and disease description](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/product-information-and-disease-description.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Clinical evidence](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/clinical-evidence.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Economic information and modeling report](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economics.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: References](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/references) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/references.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: prevalence by geography](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/prevalence.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses.md)
